Open access · US-GOV
via ClinicalTrials.gov Clinical trial
A Phase II Study of Serplulimab, Chidamide, and Rituximab Followed by R-CHOP in Newly Diagnosed Elderly Patients With MYC/BCL2 Double-Expressor Diffuse Large B-Cell Lymphoma
Authors not listed
Sun Yat-sen University · 2025
Abstract
This study is a phase II clinical trial and is divided into three stages.
Stage 1: Chemotherapy-free phase. All subjects will receive "Serplulimab, Chidamide, and Rituximab (SCR) therapy". After 2 treatment cycles, efficacy will be evaluated. Subjects who achieve CR or CMR will continue to receive 2 additional cycles of SCR therapy. Patients who do not achieve CR or CMR will proceed to Stage 2 treatment. The SCR regimen consists of rituximab 375mg/m² IV on day 1, serplulimab 300mg IV on day 2, and chidamide 30mg PO twice weekly (on days 1, 4, 8, 11, 14, and 18), repeated every 21 days.
Stage 2: Chemotherapy Phase. Subjects who achieved CR or CMR in Stage 1 will receive 4 cycles of R-CHOP therapy, while those who did not achieve CR or CMR will receive 6 cycles of R-CHOP therapy. Patients at high risk for central nervous system (CNS) involvement will receive consensus-recommended CNS prophylactic therapy (e.g., high-dose methotrexate). The R-CHOP regimen is administered at the following dosages: rituximab 375mg/m², cyclophosphamide 750mg/m², doxorubicin 50mg/m², all administered intravenously on day 1; vincristine 1.4mg/m² (max 2mg) intravenously on day 1; and prednisone 100mg orally on days 1-5. The treatment cycle is repeated every 21 days. For patients over 75 years of age or those considered frail, the R-miniCHOP regimen may be utilized.
Stage 3: Maintenance Therapy. Subjects who achieve CR/CMR or PR/PMR in Stage 2 will proceed to the maintenance phase, receiving serplulimab in combination with chidamide for 6 months. Subjects who do not achieve CR/CMR or PR/PMR in Stage 2 will be withdrawn from the study. During the maintenance phase, the regimen consists of serplulimab 300mg administered intravenously on day 1 and chidamide 30mg administered orally twice per week (specifically on days 1, 4, 8, 11, 14, and 18) of a 30-day cycle.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- ClinicalTrials.gov
- Canonical
- link ↗
- Fetched
- 2026-11-01 MST
Cite this
APA
Anonymous. (2025). A Phase II Study of Serplulimab, Chidamide, and Rituximab Followed by R-CHOP in Newly Diagnosed Elderly Patients With MYC/BCL2 Double-Expressor Diffuse Large B-Cell Lymphoma. <em>Sun Yat-sen University</em>. https://clinicaltrials.gov/study/NCT07538180
Vancouver
Anonymous. A Phase II Study of Serplulimab, Chidamide, and Rituximab Followed by R-CHOP in Newly Diagnosed Elderly Patients With MYC/BCL2 Double-Expressor Diffuse Large B-Cell Lymphoma. Sun Yat-sen University. 2025.
BibTeX
@misc{anon2025APhase,
title = {A Phase II Study of Serplulimab, Chidamide, and Rituximab Followed by R-CHOP in Newly Diagnosed Elderly Patients With MYC/BCL2 Double-Expressor Diffuse Large B-Cell Lymphoma},
author = {Anonymous},
journal = {Sun Yat-sen University},
year = {2025},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
University of Bologna 2009
Open access · US-GOV
Study of Lenalidomide(Revlimid) Plus Rituximab (Revlirit Regimen) in Elderly Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)
Hoffmann-La Roche 2010
Open access · US-GOV
Randomised Phase II Trial of Bevacizumab (AVASTIN®) in Combination With Gemcitabine or Attenuated Doses of Cisplatin and Gemcitabine as First-line Treatment of Elderly Patients With Advanced Non-squamous Non-small Cell Lung Cancer - EAGLES
SCRI Development Innovations, LLC 2012
Open access · US-GOV
Phase II Study of Bendamustine and Ofatumumab in Elderly Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma Who Are Poor Candidates for R-CHOP Chemotherapy
Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd. 2023
Open access · US-GOV
A Randomized, Double-blind, Placebo-controlled Phase I Clinical Trial to Evaluate the Safety and Tolerability of Omicron BA.4/5-Delta Strain Recombinant Novel Coronavirus Protein Vaccine (CHO Cells) in People Aged 18 Years and Above.
Amazentis SA 2018
Open access · US-GOV
A Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Impact of a Daily Dose of AMAZ-02, a Food Derived Ingredient, for 4 Months on Skeletal Muscle Energetics and Function in Healthy Elderly
Qianfoshan Hospital 2025
Open access · US-GOV